First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Rev...
September 23 2019 - 7:30AM
Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage
immunotherapy company, today announced the first presentation of
its preclinical studies, which were designed to evaluate the
combination of Enlivex’s Allocetra-OTS immunotherapy and CAR-T
therapy designed for treating solid tumors. The results, detailed
in an oral presentation today at the Joint IIS-ISCR Special 2019
Conference – The Cutting Edge of Immunology, Cancer and
Immunoncology Research – showed significantly increased duration of
survival and overall survival for study subjects who were treated
with the combination therapy, as compared to stand-alone solid
tumor CAR-T therapy. The results of these preclinical studies
showed that the mechanism of action significantly increased the
anti-tumor macrophage population surrounding the human solid tumor
microenvironment in the subjects who were treated with the
combination therapy.
"We believe that these initial findings underscore the potential
benefit of the combination of Allocetra-OTS and CAR-T across
several solid tumor types," said Dror Mevorach, M.D., Chief
Scientific and Medical Officer of Enlivex. "We believe that a
combination regimen which targets two different, complementary, and
non-overlapping mechanisms designed to harness the body's own
immune system to fight cancer has the potential to benefit patients
and should be the subject of additional research. These findings
are expected to be integrated with outcomes from a previous Phase
IIa clinical trial of Allocetra in patients post bone-marrow
transplantations, demonstrating prevention of cytokine storms –
which could serve as a dual benefit to any anti-cancer therapy that
induces severe immune reactions. The potential combination of
increased efficacy against solid cancers while maintaining a
balanced immune system is quite intriguing and planned to be be the
focus of additional future studies.”
ALLOCETRATM by Enlivex was designed to provide a novel
immunotherapy mechanism of action that targets
life-threatening clinical indications that are defined as “unmet
medical needs”, including prevention or treatment of
complications associated with bone marrow transplantations (BMT)
and/or hematopoietic stem cell transplantations (HSCT); rgan
dysfunction and acute multiple organ failure associated with
sepsis; and enablement of an effective treatment of solid tumors
via immune checkpoint rebalancing.
ABOUT ENLIVEXEnlivex is a clinical stage
immunotherapy company, developing an allogeneic drug pipeline for
immune system rebalancing. Immune system rebalancing is critical
for the treatment of life-threatening immune and inflammatory
conditions which involve an out of control immune system (e.g.
Cytokine Release Syndrome) and for which there are no approved
treatments (unmet medical needs), as well as solid tumors
immune-checkpoint rebalancing. For more information, visit
http://www.enlivex.com.
ABOUT JOINT IIS-ISCR SPECIAL 2019
CONFERENCEThe Joint IIS-ISCR Special Conference - The
Cutting Edge of Immunology, Cancer and Immunoncology
Research, is held on September 23-25, 2019 in Tel
Aviv, Israel, and hosted by the Israel Immunological Society (IIS)
the Israel Society for Cancer Research (ISCR). The conference
covers cover a wide collection of topics in contemporary immunology
and cancer research ranging from basic principles to translational
breakthroughs. Attendees include world-class speakers that will
discuss key areas in innate and acquired immunity, immune-oncology
and clinical cancer therapy. Special sessions will focus on
research hot spots including lymphocyte activation and exhaustion,
checkpoint inhibitors, Immunotherapy, Inflammation and immunity,
and mechanotransduction in the Immune System.
Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such
as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “would”, “intends,” “estimates,” “suggests,”
“has the potential to” and other words of similar meaning,
including statements regarding expected cash balances, market
opportunities for the results of current clinical studies and
preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRATM programs, which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may
affect Enlivex’s business and prospects, including the risks that
Enlivex may not succeed in generating any revenues or developing
any commercial products; that the products in development may fail,
may not achieve the expected results or effectiveness and/or may
not generate data that would support the approval or marketing of
these products for the indications being studied or for other
indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the ALLOCETRATM product line could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors
described above, investors should consider the economic,
competitive, governmental, technological and other factors
discussed in Enlivex’s filings with the Securities and Exchange
Commission, including under the heading “Risk Factors” contained in
Enlivex’s most recently filed Annual Report on Form 20-F. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law.
ENLIVEX CONTACT:
Shachar Shlosberger, CFOEnlivex Therapeutics,
Ltd.shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024